Where is Rivercell located?

Rivercell is headquartered in France.

Is Rivercell a funded company?

Rivercell is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Oct 07, 2026.

When was the latest funding round of Rivercell?

Rivercell's latest funding was a $***** Seed round on Oct 07, 2026, with participation from 4 investors.

Where does Rivercell rank among its competitors?

Rivercell ranks 27th amongst 149 active competitors, of which 21 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Rivercell, which secured $25M in Oct, 2026.

Who are the top competitors of Rivercell?

Rivercell's top competitors include HitGen, Slingshot Bioscience and InterAx Biotech. Among them, Rivercell secured the most recent funding round in October, 2026.

Rivercell - 2026 Company Profile, Funding & Competitors

Company Details

Developer of artificial intelligence models predicting cellular responses to treatment. This platform combines automated laboratory experiments with machine learning to analyze how cells change during disease. The system generates longitudinal and multimodal data by tracking cells across various conditions and environments. These results inform predictive models designed to assess the effectiveness of interventions on cellular states. The technology links live-cell imaging with gene expression data to evaluate adaptation and resistance mechanisms within biological systems.

Key Metrics

Location

France

Stage

Seed

Total Funding

$25M in 1 round

Latest Funding Round

Seed, Oct 07, 2026, $*****

Investors

HV Capital & 3 more

Ranked

27^th among 149 active competitors

Similar Companies

HitGen & 151 more

View Rivercell's full profile

Rivercell has raised a total funding of $25M over 1 round. Its latest funding round was a Seed round on Oct 07, 2026 for $*****. 4 investors participated in its latest round. Rivercell has 4 institutional investors.

Here is the list of recent funding rounds of Rivercell:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 07, 2026	6389235	Seed	6090035	2360466	3885499	5804014

Access funding benchmarks and valuations. Sign up today!

View details of Rivercell's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Rivercell include HitGen, Slingshot Bioscience and InterAx Biotech. Here is the list of Top 10 competitors of Rivercell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	HitGen 2012, Lanzhou (China), Public	Developer of DNA encoded libraries for drug discovery	$39.1M	CDH, Shiyu & 2 others	60/100
2nd	Slingshot Bioscience 2012, Berkeley (United States), Series A	Developer of next-generation synthetic cells for diagnostics and therapeutics	$46.4M	Northpond Ventures, Arch Venture Partners ... & 2 others	58/100
3rd	InterAx Biotech 2016, Villigen (Switzerland), Series A	Arrestin-based biosensors and computational methods for GPCR based drug discovery	$3.19M	Verve Ventures, Venture Kick & 6 others	55/100
4th	Passkey Therapeutics 2022, Cambridge (United States), Unfunded	Developer of multifunctional therapeutics targeting rare combinations of proteins	-	-	49/100
5th	Cavalry Biosciences 2021, San Francisco (United States), Series A	Developer of therapeutics to treat chronic and rare diseases	-	Mission BioCapital, Venrock & 2 others	46/100
6th	Aucta Pharmaceuticals 2012, New Brunswick (United States), Seed	Innovating enhanced therapeutics using technology for specialty brand and generic products	-	Shanghai Changjiang Guohong Investment Management, SDIC Venture Capital Management ... & 3 others	44/100
7th	Vectus Biosystems 2005, Rosebery (Australia), Public	Develops drug discovery platform	-	-	43/100
8th	Sequence Bio 2013, St John s (Canada), Seed	Sequence Bio is a Newfoundland and Labrador biotechnology company striving to improve how we treat diseases and develop medicines.	$5.47M	DCVC, Y Combinator & 5 others	43/100
9th	StemoniX 2014, San Diego (United States), Acquired	Engineering human brain and nerve models for neurological insights	$33.7M	EvoNexus, Gopher Angels & 19 others	41/100
10th	Signal Pharmaceuticals 1993, San Diego (United States), Acquired	Discoverer of drugs to regulate disease-related genes	$12M	Kleiner Perkins, The Vertical Group & 10 others	40/100
27th	Rivercell France, Seed	Developer of artificial intelligence models predicting cellular responses to treatment	$25M	HV Capital, HCVC & 2 others	29/100